Orellanine

Drug Profile

Orellanine

Latest Information Update: 03 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sahlgrenska University Hospital
  • Developer Oncorena Holding
  • Class Antineoplastics; Biological toxins; Mycotoxins; Oxides; Pyridines; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Renal cancer

Most Recent Events

  • 29 Sep 2016 Oncorena Holding intends to initiate a phase I/IIa trial in dialysis patients with metastatic kidney cancer in Sweden and the US in 2017
  • 29 Sep 2016 Oncorena Holdings plans a phase I/IIa trial for Renal cancer in Sweden and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top